

**GENOTYPIC ANALYSIS OF MEASLES VIRUSES
IN SOUTHERN AFRICA:
IMPLICATIONS FOR REGIONAL AND GLOBAL
ELIMINATION OF MEASLES**

Sheilagh Brigitte Smit

A dissertation submitted to the Faculty of Health Sciences,
University of the Witwatersrand, Johannesburg,
in fulfilment of the requirements for the degree of
Master of Science in Medicine

Johannesburg, 2012

DECLARATION

I, Sheilagh Smit, declare that this dissertation is my own, unaided work. It is being submitted for the degree of Master of Science in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.

Sheilagh Brigitte Smit

_____ day of _____, 2012

To my parents, Lore and Gottfried Bautz,
And my daughter, Anastasia,

Thank you
for love, support, patience
and sacrificing so much family time for so many years

ABSTRACT

Measles is a vaccine-preventable disease. Implementation of global vaccination programmes has resulted in a dramatic decrease in measles-related deaths, from 2.6 million in 1980 to 164 000 in 2008. To support the global measles elimination goal, laboratories provide case-based surveillance which includes both serological diagnosis and viral characterisation using molecular platforms.

In this study, conventional hemi-nested amplification methods were developed to detect the nucleoprotein- and haemagglutinin-genes of measles virus, in specimens collected for rash-surveillance programmes in Africa. Viral characterisation involved amplicon sequencing and phylogenetic analyses of 1402 PCR-positive specimens (2655 specimens tested, 52.8% PCR-positive) with sequence submission to global databases. Only imported strains of genotypes B2, B3, D2, D4 and D8, have been detected in South Africa since 2002, demonstrating the successful interruption of transmission of endemic strains. Genotypic analyses of specimens from African countries provided information relating to strain origins, as well as temporal and spatial data relevant to the molecular epidemiology of measles in Southern Africa.

PUBLICATIONS AND PRESENTATIONS

Publications arising from MSc

1. **Smit SB**, Hardie D, Tiemessen CT.
Measles virus genotype B2 is not inactive: evidence of continued circulation in Africa.
J Med Virol. 2005 Dec;77(4):550-7.
2. Neverov AA, Riddell MA, Moss WJ, Volokhov DV, Rota PA, Lowe LE, Chibo D, **Smit SB**, Griffin DE, Chumakov KM, Chizhikov VE.
Genotyping of measles virus in clinical specimens on the basis of oligonucleotide microarray hybridization patterns.
J Clin Microbiol. 2006 Oct;44(10):3752-9.
3. Rota J, Lowe L, Rota P, Bellini W, Redd S, Dayan G, van Binnendijk R, Hahne S, Tipples G, Macey J, Espinoza R, Posey D, Plummer A, Bateman J, Gudino J, Cruz-Ramirez E, Lopez-Martinez I, Anaya-Lopez L, Holy Akwar T, Giffin S, Carrion V, de Filippis AM, Vicari A, Tan C, Wolf B, Wytovich K, Borus P, Mbugua F, Chege P, Kombich J, Akoua-Koffi C, **Smit S**, Bukenya H, Bwogi J, Baliraine FN, Kremer J, Muller C, Santibanez S.
Identical genotype B3 sequences from measles patients in 4 countries, 2005.
Emerg Infect Dis. 2006 Nov;12(11):1779-81.
4. Lemma E, **Smit SB**, Beyene B, Nigatu W, Babaniyi OA.
Genetic characterization and progression of B3 measles genotype in Ethiopia: a study of five measles outbreak cases.
Ethiop Med J. 2008 Jan;46(1):79-85.
5. Kremer JR, Nkwembe E, Oyefolu AOB, **Smit SB**, Pukuta E, Omilabu SA, Adu F, Muyembe Tamfum JJ, Muller CP.
MV strain diversity reflects differences in measles epidemiology and control in Nigeria and the Democratic Republic of the Congo.
Emerg Infect Dis. 2010 Nov;16(11):1724-30.
6. Adagba M, Akoua-Koffi C, Traore I, **Smit S**, Ekaza E, Kadjo H, Dosso M, Featherstone DA.
Detection of viral RNA by RT-PCR from serum for molecular diagnosis of measles.
Afr J Med Med Sci. 2010 Dec; 39(4):277-84.
7. Baliraine FN, Bwogi J, Bukenya H, Seguya R, Kabaliisa T, Kisakye A, Mbabazi W, **Smit SB**.
Possible interruption of indigenous Measles virus transmission in Uganda, 2006-2009.
Emerg Infect Dis. 2011 Jan;17(1):110-113.
8. Rota PA, Brown K, Mankertz A, Santibanez S, Shulga S, Muller C, Hübschen JM, Siqueira M, Beirnes J, Ahmed H, Triki H, Al-Busaidy S, Dosseh A, Byabamazima C, **Smit S**, Akoua-Koffi C, Bwogi J, Bukenya H, Wairagkar N, Ramamurty N, Incomserb P,

Pattamadilok S, Jee Y, Lim W, Xu W, Komase K, Takeda M, Tran T, Castillo-Solorzano C, Chenoweth P, Brown D, Mulders MN, Bellini WJ, Featherstone D.
Global distribution of measles genotypes and measles molecular epidemiology.
J Infect Dis. 2011 Jul; 204 Suppl 1:S514-23.

Publications arising from other work performed during MSc

1. Leroy EM, Rouquet P, Formenty P, Souquiere S, Kilbourne A, Froment JM, Bermejo M, **Smit S**, Karesh W, Swanepoel R, Zaki SR, Rollin PE.
Multiple Ebola virus transmission events and rapid decline of central African wildlife.
Science. 2004 Jan 16;303(5656):387-90. Erratum in: Science. 2004 Jan 20;303(5658):628.
2. Venter M, **Smit SB**, Leman P, Swanepoel R.
Phylogenetic evidence of widespread distribution of genotype 3 JC virus in Africa and identification of a type 7 isolate in an African AIDS patient.
J Gen Virol. 2004 Aug;85(Pt 8):2215-9.
3. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, Borchert M, Rollin PE, Sleurs H, Campbell P, Tshioko FK, Roth C, Colebunders R, Pirard P, Mardel S, Olinda LA, Zeller H, Tshomba A, Kulidri A, Libande ML, Mulangu S, Formenty P, Grein T, Leirs H, Braack L, Ksiazek T, Zaki S, Bowen MD, **Smit SB**, Leman PA, Burt FJ, Kemp A, Swanepoel R; International Scientific and Technical Committee for Marburg Hemorrhagic Fever Control in the Democratic Republic of the Congo.
Marburg hemorrhagic fever associated with multiple genetic lineages of virus.
N Engl J Med. 2006 Aug 31;355(9):909-19.
4. Swanepoel R, **Smit SB**, Rollin PE, Formenty P, Leman PA, Kemp A, Burt FJ, Grobbelaar AA, Croft J, Bausch DG, Zeller H, Leirs H, Braack LE, Libande ML, Zaki S, Nichol ST, Ksiazek TG, Paweska JT; International Scientific and Technical Committee for Marburg Hemorrhagic Fever Control in the Democratic Republic of Congo.
Studies of reservoir hosts for Marburg virus.
Emerg Infect Dis. 2007 Dec;13(12):1847-51.
5. Caidi H, Abernathy ES, Benjouad A, **Smit S**, Bwogi J, Nanyunja M, El Aouad R, Icenogle J.
Phylogenetic analysis of rubella viruses found in Morocco, Uganda, Cote d'Ivoire and South Africa from 2001 to 2007.
J Clin Virol. 2008 May;42(1):86-90.
6. Abernathy ES, Hübschen JM, Muller CP, Jin L, Brown D, Komase K, Mori Y, Xu W, Zhu Z, Siqueira MM, Shulga S, Tikhonova N, Pattamadilok S, Incomserb P, **Smit SB**, Akoua-Koffi C, Bwogi J, Lim WWL, Woo GKS, Triki H, Jee Y, Mulders MN, Bispo de Filippis AM, Ahmed H, Ramamurty N, Featherstone D, Icenogle JP.
Status of global virologic surveillance for rubella viruses.
J Infect Dis 2011 Jul; 204 Suppl 1:S524-32.

Presentations

Local Meetings attended:

1. Rubella control workshop: global, regional and national perspectives. 15-16 March 2004, NICD, South Africa. Oral presentation entitled “Molecular characterization of South African rubella strains”.
2. Communicable Disease Co-ordinators meeting, 17 March 2004, NICD, South Africa. Oral presentation entitled “Measles outbreak 2003”.
3. Virology Africa congress, 8-11 November 2005, Cape Town. Oral presentation entitled “Molecular analysis of measles viruses in southern Africa”.

International WHO meetings attended:

1. Second WHO Global Measles and Rubella Laboratory Network Meeting, 13-14 October 2003, Cape Town. Oral presentation entitled “Detection of measles virus in clinical specimens”.
2. Southern Africa EPI Managers’ Meeting, 10-12 March 2004, Gaborone, Botswana. Oral presentation entitled “Molecular epidemiology of Measles Virus in southern Africa”.
3. First Measles and Yellow Fever Laboratory Directors Meeting, 2-4 August 2004, Dakar, Senegal. Two oral presentations entitled “Activity report of the measles regional reference laboratory for the WHO southern African region: NICD, South Africa” and “Genotypic analysis of Measles Virus from dried blood spots”.
4. Second Measles and Yellow Fever Laboratory Directors Meeting, 2-3 August 2005, Entebbe, Uganda. Oral presentation entitled “Southern Block report on measles diagnostics”.
5. Third WHO Global Measles and Rubella Laboratory Network Meeting, 25-26 August 2005, Geneva, Switzerland. Oral presentation entitled “Virological surveillance update: South Africa 2003-2005”.
6. Fourth WHO Global Measles and Rubella Laboratory Network Meeting, 28-30 August 2006, Geneva, Switzerland. Oral presentation entitled “Characterization of viruses identified in the African region and challenges in improving surveillance”.
7. Joint Measles and Polio Laboratory Directors Workshop, 24 – 26 July 2007, Accra, Ghana. Oral presentation entitled “progress report RRL NICD molecular aspects 2006-2007”.
8. Fifth WHO Global Measles and Rubella Laboratory Network Meeting, 26-28 September 2007, Geneva, Switzerland. Oral presentation entitled “Virological surveillance update: South Africa 2006-2007”.
9. Polio/Measles/Yellow Fever Laboratory Directors Workshop, 8-11 September 2008, Lusaka, Zambia. Oral presentation entitled “Update on Measles Virus genotypes in the African Region”.

10. Sixth WHO Global Measles and Rubella Laboratory Network Meeting, 23-25 September 2008, Geneva, Switzerland. Oral presentation entitled "Characterization of measles and rubella viruses identified in the African Region".
11. Polio and Measles Laboratory Directors Meeting, 6-10 July 2009, Kampala, Uganda. Oral presentation entitled "Update of the genetic characteristics of recent measles and rubella viruses detected in the African region".
12. The 7th Global Measles and Rubella Laboratory Network Meeting. 12-14 October 2009, WHO Headquarters, Geneva, Switzerland. Oral presentation entitled "Monitoring measles outbreaks in the African Region – southern African countries 2009".
13. Polio and Measles Laboratory Directors Meeting, 15-16 July 2010, Harare, Zimbabwe. Oral presentation entitled "Update of the genetic characteristics of recent measles and rubella viruses detected in the African region".
14. The 8th Global Measles and Rubella Laboratory Network Meeting. 20-22 September 2010, WHO Headquarters, Geneva, Switzerland. Oral presentation entitled "Molecular surveillance in the African Region".
15. The 9th Global Measles and Rubella Laboratory Network Meeting. 19-21 September 2011, WHO Headquarters, Geneva, Switzerland. Oral presentation entitled "Molecular surveillance in the African Region".
16. Measles and Yellow Fever Laboratory Directors Meeting, 20-21 October 2011, Harare, Zimbabwe. Oral presentation entitled "Measles molecular surveillance in the African Region".

ACKNOWLEDGEMENTS

My sincere thanks and appreciation to Dr Monica Birkhead for support and help

Supervisor Professor Caroline T. Tiemessen

NICD-NHLS, the Polio Research Foundation, the Department of Health and the World Health Organization for funding

Measles serology laboratory staff, NICD for IgM serology testing

Respiratory virus isolation laboratory staff, NICD for viral isolation

Clean laboratory staff, NICD for provision of flasks of Vero-hSLAM cultures

World Health Organization, Geneva

Measles section, Centers for Disease Control, Atlanta

World Health Organization, Measles Laboratory Network

World Health Organization, African Region

Regional Reference Laboratory, Pasteur Institute, Abidjan, Côte d'Ivoire

Regional Reference Laboratory, Uganda Virus Research Institute, Entebbe, Uganda

National Laboratories of the southern African countries

National Laboratories of other African countries

TABLE OF CONTENTS

	Page
DECLARATION	ii
DEDICATION	iii
ABSTRACT	iv
PUBLICATIONS AND PRESENTATIONS	v
ACKNOWLEDGEMENTS	ix
TABLE OF CONTENTS	x
LIST OF TABLES	xiii
LIST OF FIGURES	xiv
LIST OF ABBREVIATIONS	xvii
1.0 INTRODUCTION AND LITERATURE REVIEW	1
1.1 Clinical disease	1
1.2 Measles in history	3
1.3 The virus	5
1.4 Virus isolation and development of vaccines	10
1.5 Cellular receptors and pathogenesis	11
1.6 Immune responses	14
1.7 Measles control programmes	16
1.8 Laboratory diagnosis and confirmation	20
1.9 Global surveillance	22
1.10 Nomenclature	25
1.11 Objectives of the study	26
2.0 MATERIALS AND METHODS	27
2.1 Specimens	27
2.1.1 Specimen types	27
2.1.1 Specimen numbers and country of origin	28
2.2 Extraction of RNA	30
2.3 Primers, RT-PCR and nested PCR (N-gene)	30
2.4 Comparison of detection of MV RNA from urine <i>versus</i> serum	31
2.5 Sensitivity of the N-gene RT-PCR and hemi-nested PCR	33
2.6 Primers, RT-PCR and nested PCR (H-gene)	35

2.7	MV positive control for RT-PCR	37
2.8	Negative control for RNA extraction, RT-PCR and hemi-nested PCR	38
2.9	Agarose gel electrophoresis	38
2.10	Determination of sensitivity of the RT-PCR and the hemi-nested PCR	39
2.11	Preparation of PCR products for sequencing	39
2.12	Sequencing reactions	40
2.13	Sequence editing and phylogenetic analysis	41
2.14	Naming of sequences	41
3.0	RESULTS AND DISCUSSION	43
3.1	Genotype B2	43
3.1.1	Outbreak in Cape Town, South Africa, 2002	43
3.1.2	Luanda, Angola	44
3.1.3	Specimens	44
3.1.4	Analysis of N-450 sequences	44
3.1.5	Sequence analysis of entire H-gene	47
3.1.6	Evidence of continued circulation of genotype B2 viruses	50
3.2	Genotype D2	57
3.2.1	Southern African outbreak 2003-2005	57
3.3	Genotype D4	63
3.3.1	Sporadic cases	63
3.3.2	Outbreak 2006	64
3.4	Genotype D8	72
3.4.1	Sporadic cases	72
4.0	CONCLUDING REMARKS	75
5.0	REFERENCES	78
6.0	APPENDICES	100
	Appendix A: Listing of WHO "EPID" Country codes, ISO3 Country codes and English name	100
	Appendix B: Extraction of measles virus RNA from urine, virus isolates, throat swabs, oral fluid and serum	102
	Appendix C: Primer information	103

Appendix D: RT-PCR for measles virus N-gene RNA	106
Appendix E: Hemi-nested PCR for measles N-gene	107
Appendix F: RT-PCR for measles virus H-gene RNA	108
Appendix G: Hemi-nested PCR for measles H-gene	109
Appendix H: Agarose gel electrophoresis	110
Appendix I: Purification of PCR products in preparation for sequencing	111
Appendix J: Sequencing of measles PCR-positive specimens	112
Appendix K: List of WHO measles virus reference strains (WHO, 2012)	114
Appendix L: Alignment of predicted amino acid sequences of the carboxyl-terminal region of the nucleoprotein of the MV reference strains	115
Appendix M: Ethics clearance certificate	117

LIST OF TABLES

Table		Page
1.1	Structural and regulatory proteins of measles virus (Bankamp et al., 2005, Moss & Griffin, 2009, Palosaari et al., 2003, Patterson et al., 2000).	8
2.1	Numbers of sequences and genotypes obtained are shown per year per country. The total number of specimens tested and sequences obtained are also indicated per year of this study.	29
3.1	Comparison of the predicted haemagglutinin amino acid sequences of the recent B2 viruses with the B-clade reference strains in relation to reference strain genotype A.	49
3.2	Amino acid and nucleotide distance matrix of selected genotype B2 N-gene sequences.	56
3.3	Amino acid and nucleotide distance matrix of selected genotype D2 N-gene sequences.	61
3.4	Amino acid and nucleotide distance matrix for selected genotype D4 group 1 N-gene sequences.	68
3.5	Amino acid and nucleotide distance matrix for selected genotype D4 group 2 N-gene sequences.	69
3.6	Amino acid and nucleotide distance matrix for selected genotype D4 group 3 N-gene sequences.	70
3.7	Amino acid and nucleotide distance matrix for selected genotype D4 group 4 N-gene sequences.	71
C1	Details of the N-gene primers used in the project. Numbering is according to the Edmonston strain of MV (Genbank accession number U01987).	103
C2	Measles virus H-gene sequence and primer map. Numbering is according to the Edmonston strain of MV (Genbank accession number U03669).	104

LIST OF FIGURES

Figure		Page
1.1	Clinical features of typical measles time-course from onset of illness (WHO, 2007).	2
1.2	Diagram of a measles virus particle and correlation with the genetic map (Griffin, 2007, Murray <i>et al.</i> , 1998).	6
1.3	Immune responses in acute measles infection (Redd <i>et al.</i> , 1999).	16
2.1	Comparison of results obtained using urine versus serum (a) N-gene RT-PCR. Lanes 1 and 24: molecular weight marker 100 bp ladder; Lanes 2-7 urine specimens; Lanes 8-21 serum specimens; lane 22: negative control; Lane 23: positive control. (b) hemi-nested PCR of the RT PCR-negative specimens shown in (a). Lanes 1 and 21: molecular weight marker 100 bp ladder; Lanes 2 and 3: urine specimens; Lanes 4-17 serum specimens; Lane 18: nested negative control; Lane 19: nested positive control; Lane 20: negative control for the nested reagents.	32
2.2	Gel analyses of the N-gene RT-PCRs of the serial dilution of the synthetic RNA positive control using primer sets (a) N16/MV63 and (b) MeV216/MeV214.	34
2.3	Gel analyses of the nested PCR products generated with MV60/MV63 using the RT-PCR products obtained with (a) N16/MV63; the vaccine RNA control yields a 599 bp product, while the synthetic RNA control yields an 819 bp product (b) MeV214/MeV216; the vaccine RNA control yields a 634 bp product, while the synthetic RNA control yields an 854 bp product and (c) final dilution of both sets of primers (insufficient lanes on gel apparatus).	35
3.1	Phylogenetic analysis of the partially-sequenced N genes of MV from specimens collected during the outbreaks in South Africa and Angola (in bold font). The N-450 sequences were compared to the WHO reference sequences; the names of the reference strains have been deleted for clarity and have been replaced with the designated genotype (WHO, 2003). The unrooted neighbour-joining tree (number of nucleotide changes algorithm) was generated by bootstrap analysis (1000 replicates) using MEGA3.1 software. Only bootstrap frequencies greater than 70% are shown. GenBank accession numbers are indicated in brackets after the sequence names.	46
3.2	Alignment of the predicted amino acid sequences of the variable carboxyl-terminal region of the nucleoprotein of the outbreak B2 viruses with the B-clade reference strains by comparison to reference strain genotype A.	47

3.3	Phylogenetic analysis of the complete H-gene sequences of MV from the Cape Town and Luanda outbreaks. The unrooted neighbour-joining tree (Kimura 2-parameter algorithm) was generated by bootstrap analysis (1000 replicates). Only bootstrap frequencies higher than 70% are shown. The scale bar indicates nucleotide substitutions per site.	48
3.4	Phylogenetic analysis of the N-450 sequences of genotype B2 MV from specimens collected subsequent to the 2002 South African outbreak. Sequences from this study are shown in bold font. The unrooted neighbour-joining tree was generated by bootstrap analysis (1000 replicates) using MEGA 3.1 software. Only bootstrap frequencies greater than 70% are shown.	52
3.5	Phylogenetic analysis of predicted amino acid translation of selected genotype B2 sequences based on the unique N-450 sequences. Sequences from this study are shown in bold font.	53
3.6	Alignment of the predicted amino acid sequences of the variable carboxyl-terminal region of the nucleoprotein of all unique B2 viruses with the B-clade reference strains by comparison to reference strain genotype A.	54-55
3.7	Phylogenetic analysis of the N-450 sequences of genotype D2 MV from the 2003-2005 South African outbreak, from EQA submissions from the southern block countries and the WHO reference sequences, shown only as designated genotype for clarity (WHO, 2003). Sequences from this study are shown in bold font. The unrooted minimum evolution tree was generated by bootstrap analysis (1000 replicates) using MEGA 3.1 software. Only bootstrap frequencies greater than 70% are shown.	59
3.8	Minimum evolution amino acid tree using predicted translations of the nucleotide sequences of genotype D2 MV depicted in Figure 3.7 above. Sequences in bold font are from this study.	60
3.9	Alignment of selected predicted amino acid translations of the N-gene genotype D2 sequence data.	62
3.10	Phylogenetic analysis of selected partially-sequenced N genes of genotype D4 MV. The unrooted neighbour-joining tree was generated by bootstrap analysis (1000 replicates) using MEGA 3.1 software. Only bootstrap frequencies greater than 70% are shown. Sequences from this study are shown in bold.	65
3.11	Phylogenetic analysis of selected predicted amino acid sequences of the 150 carboxyl-terminal residues of the N-gene of genotype D4 strains. Sequences from this study are shown in bold.	66
3.12	Alignment of selected predicted amino acid translation of the genotype D4 sequence data.	67
3.13	Phylogenetic analysis of selected N-450 sequences of genotype D8	73

MV. The unrooted neighbour-joining tree was generated by bootstrap analysis (1000 replicates) using MEGA 3.1 software. Only bootstrap frequencies greater than 70% are shown. Sequences from this study are shown in bold.

3.14	Phylogenetic analysis of selected predicted amino acid sequences of the 150 carboxyl-terminal residues of the N-gene of genotype D8 strains. Sequences from this study are shown in bold.	74
C1	Measles virus nucleoprotein gene sequence and primer map.	103
C2	Measles virus haemagglutinin gene sequence and primer map.	104

LIST OF ABBREVIATIONS

AA	amino acid
ADEM	acute disseminated encephalomyelitis, also known as acute post-infectious measles encephalomyelitis
B95-a	adherent Marmoset lymphoblastoid B cell line transformed with Epstein-Barr virus
BDX	BigDye® Xterminator
bp	base pair
CDC	Centres for Disease Control and Prevention, Atlanta, USA
CD46	also known as membrane cofactor protein, ubiquitously expressed on primate cells, protects against complement-mediated cell lysis; cellular receptor of laboratory-adapted strains of measles virus
CIF	case investigation form
CMI	cell-mediated immunity
CPE	cytopathic effect
cp/μl	copies per microlitre
CV-1	continuous cell line derived from the African green monkey kidney
DBS	dried blood spot
dNTP	deoxyribonucleotide triphosphate
DNA	deoxyribonucleic acid
DRC	Democratic Republic of the Congo
EDTA	ethylenediaminetetraacetic acid
EGFP	Enhanced green fluorescent protein
EIA	enzyme immunoassays also called enzyme-linked immunosorbent assays ELISA
EPI	Expanded Programme for Immunization
EPID	Epidemiological Country Code
EQA	external quality assurance
F	fusion protein
H	haemagglutinin protein
HIV-1	Human Immunodeficiency virus type 1
IgG	Immunoglobulin class G
IgM	Immunoglobulin class M
ISO3	Three letter country code specified by the International Organisation for Standardisation
L	large protein
LabNet	WHO measles Laboratory Network
M	matrix protein
MCV	measles containing vaccine

MCV1	first dose of measles containing vaccine
MCV2	second dose of measles containing vaccine
MIBE	measles inclusion body encephalitis
MVi	Measles virus sequence obtained from viral isolate
MVs	Measles virus sequence obtained from clinical specimen
mRNA	messenger RNA
μl	microlitre
mIU	milli-international units
MMR	vaccine containing attenuated strains of measles, mumps and rubella viruses
MR	vaccine containing attenuated strains of measles and rubella viruses
MV	measles virus
N	nucleoprotein
N-450	the 450 nucleotides coding for the carboxyl-terminal 150 amino acids of the MV nucleoprotein
ng	nanogram
NICD	National Institute for Communicable Diseases, a division of the National Health Laboratory Service
NL	National Laboratory
OF	Oral Fluid
ORI	Outbreak Response Immunisation
P	phosphoprotein
PCR	polymerase chain reaction
pmol	picomole
RRL	Regional Reference Laboratory of the WHO Measles and Rubella LabNet
RT-PCR	reverse transcriptase-polymerase chain reaction
RNA	ribonucleic acid
SIA	Supplementary Immunisation Activity
SLAM	Signaling Lymphocyte Activation Molecule, also known as CD150
SMC	suspected measles case
SSPE	Subacute sclerosing panencephalitis
TCID ₅₀	Tissue Culture Infectious Dose causing infection in 50% of inoculated cell cultures
TBE	TRIS–borate-EDTA buffer
TE	TRIS buffer with EDTA
TS	Throat Swab
UV	ultraviolet
Vero	continuous cell line derived from the African green monkey kidney (derived from <u>Verdant</u> =green reno=kidney)
Vero-hSLAM	recombinant Vero cells expressing the human SLAM molecule

WHO	World Health Organisation
WT	wild-type virus